A randomised, placebo controlled study of alfuzosin in patients undergoing trial without catheter following admission with acute urinary retention

Submission date	Recruitment status No longer recruiting	Prospectively registered		
12/09/2003		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
12/09/2003	Completed	[X] Results		
Last Edited 21/02/2020	Condition category Signs and Symptoms	[] Individual participant data		
	Signs and Symptoms			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr T Shah

Contact details

Urology Department St. Luke's Hospital Little Horton Lane Bradford United Kingdom BD5 0NA

Additional identifiers

Protocol serial number N0050072990

Study information

Scientific Title

A randomised, placebo controlled study of alfuzosin in patients undergoing trial without catheter following admission with acute urinary retention

Study objectives

To evaluate the role of an alpha-1 adrenoceptor antagonist in the treatment of acute urinary retention. To test the hypothesis that oral alfuzosin will increase the proportion of men in acute urinary retention who void after trial without catheter (AVR).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Signs and Symptoms: Acute urinary retention

Interventions

Randomised, placebo-controlled study at two centres. The aim of the study is to evaluate the effectiveness of alpha-adrergic blocker alfuzosin SR 5 mg given to patients in acute urinary retention prior to trial without catheter (TWOC). If successful it would reduce the number of operative treatments for patients with bladder outlet obstruction due to benign prostatic hyperplasia (BPH).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Alfuzosin

Primary outcome(s)

Successful outcome will be measured in terms of spontaneous voiding

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/12/2000

Eligibility

Key inclusion criteria

Patients with acute urinary retention who meet inclusion criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Male

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

31/12/2000

Locations

Countries of recruitment

United Kingdom

England

Study participating centre St. Luke's Hospital

Bradford United Kingdom BD5 0NA

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Industry

Funder Name

Lorex Synthelabo Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details results	Date created Date added Peer reviewed? Patient-facing?			
Results article		01/10/2002		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes